A Prospective Observational Study in Patients With Wet Ag... | EligiMed

A Prospective Observational Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America

CompletadoClinicalTrials.gov

ID: NCT03470103Tipo: OBSERVATIONALInicio: 28 de mar de 2018Fin estimado: 15 de ene de 2021

Traducción no disponible, mostrando original

Resumen

The main objectives of this observational cohort study are to describe the use of intravitreal aflibercept and to describe follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical practice in Latin America for a study population of treatment naive patients and those who have received prior therapy (anti-VEGF injections, laser, steroids, etc.) and are being switched to intravitreal aflibercept injection.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Age: ≥18 years of age for DME patients,
Age: ≥55 for wAMD patients
Decision to treat with intravitreal aflibercept in the study eye prior to patient enrolment as per the physician's routine clinical practice and following the local Product monograph recommendations. Patients who are treatment naïve (no previous intravitreal treatment received, including, anti- VEGF agents, steroids, steroid implants and/or PDT) and patients that are switching from a different anti-VEGF therapy are both eligible to be included. DME patients that have received previous laser only will be classified as treatment naïve.
If of childbearing potential, female willing to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of aflibercept

Criterios de exclusión

Patients participating in an investigational program with interventions outside of routine clinical practice.
Patients currently being treated with intravitreal aflibercept in the study eye.
Patients who are hypersensitive to this drug, to any ingredient in the formulation, or to any component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the local product monograph.
Ocular or peri-ocular infection in either eye.
Active intraocular inflammation in the study eye.
Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
Patients with advanced glaucoma, visually significant cataracts, or any eye disease likely to require surgery during the study period in the study eye.
Concomitant ocular or systemic administration of drugs that could interfere with or potentiate the mechanism of action of intravitreal aflibercept, including anti-VEGF agents.
Patients receiving a different anti-VEGF agent other than intravitreal aflibercept for the fellow eye.

Intervenciones

drug

Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

Use of intravitreal aflibercept in routine clinical practice in Latin America

Ubicaciones

Many locations

Multiple Locations, Argentina

Patrocinadores

PrincipalBayer

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.